Market expansion PetDx operates in canine cancer detection with OncoK9, a first-in-class MCED test, presenting a scalable, recurring revenue opportunity through veterinary clinics and pet care networks seeking advanced diagnostics.

Strategic partnerships PetDx previously collaborated with Petco and has strong clinic adoption; potential sales opportunities exist to broaden distribution through pet retailers, hospital networks, and veterinary associations seeking integrated screening programs.

Technology leverage The use of next-generation sequencing and proprietary bioinformatics positions PetDx to upsell additional genomics-based tests or longitudinal monitoring services for canine patients within existing OncoK9 workflows.

Funding traction With substantial funding and a recent leadership hire, PetDx is in growth mode, signaling a likelihood of expanding sales teams, clinical education programs, and enterprise-grade deployment for larger veterinary groups.

Financial signal Current revenue range and Series B funding indicate a scalable business model; target opportunities include multi-clinic accounts, multi-site hospital groups, and value-based offerings for preventive oncology programs.